LCN2 and breast cancer: A liposomal formulation with an antibody targeting intercellular adhesion molecule-1 (ICAM) loaded with siRNA-LCN2 has previously shown stronger binding and internalization in triple-negative MDA-MB-231 breast cancer cells than in non-cancerous cells [74].